This Week in HIV Research: A Long-Acting Popularity Contest

This Week in HIV Research: A Long-Acting Popularity Contest

This may be the last edition of This Week in HIV Research we'll publish in 2018, but we're still going strong as we hit the home stretch. This week's slate of four recently published HIV-related studies features these findings:

Think the most popular form of long-acting HIV treatment is the one with least-frequent dosage? Think again.

Telehealth may be a valuable tool in improving HIV pre-exposure prophylaxis (PrEP) uptake among young men of color who have sex with men.

This may be the last edition of This Week in HIV Research we'll publish in 2018, but we're still going strong as we hit the home stretch. This week's slate of four recently published HIV-related studies features these findings:

Think the most popular form of long-acting HIV treatment is the one with least-frequent dosage? Think again.

Telehealth may be a valuable tool in improving HIV pre-exposure prophylaxis (PrEP) uptake among young men of color who have sex with men.

TheBodyPRO.com is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.